[go: up one dir, main page]

DK2552484T3 - Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer - Google Patents

Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer Download PDF

Info

Publication number
DK2552484T3
DK2552484T3 DK11763340.4T DK11763340T DK2552484T3 DK 2552484 T3 DK2552484 T3 DK 2552484T3 DK 11763340 T DK11763340 T DK 11763340T DK 2552484 T3 DK2552484 T3 DK 2552484T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
reducing parathyroid
parathyroid levels
levels
Prior art date
Application number
DK11763340.4T
Other languages
English (en)
Inventor
Samir P Tabash
Charles W Bishop
Joel Z Melnick
Eric J Messner
P Martin Petkovich
Jay A White
Original Assignee
Opko Ireland Global Holdings Ltd
Opko Renal Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Ireland Global Holdings Ltd, Opko Renal Llc filed Critical Opko Ireland Global Holdings Ltd
Application granted granted Critical
Publication of DK2552484T3 publication Critical patent/DK2552484T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK11763340.4T 2010-03-29 2011-03-29 Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer DK2552484T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31874110P 2010-03-29 2010-03-29
US40519610P 2010-10-20 2010-10-20
PCT/US2011/030404 WO2011123476A1 (en) 2010-03-29 2011-03-29 Methods and compositions for reducing parathyroid levels

Publications (1)

Publication Number Publication Date
DK2552484T3 true DK2552484T3 (da) 2020-04-14

Family

ID=44712595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11763340.4T DK2552484T3 (da) 2010-03-29 2011-03-29 Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer

Country Status (18)

Country Link
US (2) US11672809B2 (da)
EP (2) EP3636280B1 (da)
KR (1) KR102125424B1 (da)
CN (2) CN105796530A (da)
CA (1) CA2797537C (da)
CY (1) CY1123095T1 (da)
DK (1) DK2552484T3 (da)
ES (2) ES2783980T3 (da)
HK (1) HK1222132A1 (da)
HR (1) HRP20200577T1 (da)
HU (1) HUE048464T2 (da)
LT (1) LT2552484T (da)
PL (1) PL2552484T3 (da)
PT (1) PT2552484T (da)
RS (1) RS60087B1 (da)
SI (1) SI2552484T1 (da)
SM (1) SMT202000167T1 (da)
WO (1) WO2011123476A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
EP2679228B1 (en) 2006-06-21 2018-03-21 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
KR101759244B1 (ko) 2007-04-25 2017-07-18 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2321273B1 (en) * 2008-07-24 2014-11-19 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
SI2552484T1 (sl) 2010-03-29 2020-07-31 Opko Ireland Global Holdings, Ltd. Postopki in sestavki za znižanje ravni paratiroidnega hormona
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CA3018019A1 (en) * 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
CA3037444A1 (en) * 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
AU2019248829B2 (en) 2018-04-03 2025-02-06 Opko Ireland Global Holdings, Ltd. Use of calcifediol in bariatric surgery patients
MX2020011741A (es) * 2019-02-06 2021-03-02 Eirgen Pharma Ltd Método para controlar la evolución del hiperparatiroidismo mediante calcifediol, y composiciones para usarse en el mismo.
CN112386601B (zh) * 2019-08-19 2022-01-07 香港理工大学深圳研究院 维生素d补充制剂及其应用
US12313478B2 (en) 2021-10-01 2025-05-27 Sensitronics, LLC Low drift force sensor with capacitive capability
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS55139320A (en) 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
JPS57188520A (en) 1981-05-15 1982-11-19 Kureha Chem Ind Co Ltd Antihyperkalemia
US4442093A (en) 1981-05-15 1984-04-10 Kureha Kagaku Kogyo Kabushiki Kaisha Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia
JPS5832823A (ja) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd 脱癌剤
JPS58206524A (ja) 1982-05-26 1983-12-01 Kureha Chem Ind Co Ltd 抗腫瘍剤
US4448721A (en) 1982-09-20 1984-05-15 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 compounds and process for preparing same
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
EP0207638B1 (en) 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US5167965A (en) 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4892821A (en) 1987-07-08 1990-01-09 Taisho Pharmaceutical Co., Ltd. Method for preparing vitamin D compounds
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JP2525478B2 (ja) 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JPH04198129A (ja) 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンｄ製剤
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
ATE144424T1 (de) 1991-04-09 1996-11-15 Takeda Chemical Industries Ltd Stabilisiertes vitamin d arzneimittel
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
ATE211387T1 (de) 1992-06-22 2002-01-15 Bone Care Int Inc Oral 1alpha-hydroxyprevitamin d
US5354743A (en) 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
IL110117A0 (en) 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
EP0769936A1 (en) 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
DE69535461T2 (de) 1994-10-21 2008-09-25 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium-rezeptor aktive verbindungen
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US20020183288A1 (en) 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
NZ501318A (en) 1995-09-21 2001-07-27 Wisconsin Alumni Res Found Medicaments containing 25 hydroxy vitamin D (calcitriol) derivatives
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
US5939408A (en) 1996-05-23 1999-08-17 Hoffman-La Roche Inc. Vitamin D3 analogs
NO971934L (no) 1996-05-23 1997-11-24 Hoffmann La Roche Flourinerte vitamin D3 -analoger
ID18079A (id) 1996-08-26 1998-02-26 Takeda Chemical Industries Ltd Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
EP0935523B1 (en) 1996-10-28 2004-09-29 Inc. General Mills Embedding and encapsulation of controlled release particles
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンｄ化合物を配合した眼内投与剤
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
US5872113A (en) 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
ATE322892T1 (de) 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ
US6096876A (en) 1997-08-06 2000-08-01 Shriners Hospitals For Children 1-α-hydroxylase materials and methods
AU9376998A (en) 1997-09-02 1999-03-22 Johns Hopkins University School Of Medicine, The Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US5919986A (en) 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
JPH11158074A (ja) 1997-12-03 1999-06-15 Hayashi Tomie 高アミノ酸付加活性型ビタミンｄ強化組成物
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
CN1301298A (zh) 1998-03-25 2001-06-27 卡坦诺根公司 用于预防和治疗癌症的方法
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
US8133694B2 (en) 1998-06-25 2012-03-13 Immundiagnostik Ag Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
US6214376B1 (en) 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
DE69942928D1 (de) 1998-08-27 2010-12-23 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
ATE429813T1 (de) 1998-10-09 2009-05-15 Gen Mills Inc Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
JP2000206312A (ja) 1998-11-12 2000-07-28 Olympus Optical Co Ltd 光学素子
MXPA01006108A (es) 1998-12-17 2002-09-18 Alza Corp Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1745787B1 (en) 1999-04-01 2016-11-09 Johns Hopkins University NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1-alpha 25-DIHYDROXY VITAMIN D3
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
WO2000072831A1 (en) 1999-05-27 2000-12-07 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
HK1046851A1 (en) 1999-08-31 2003-01-30 Chugai Seiyaku Kabushiki Kaisha Soft capsules
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
EP2070911A2 (en) 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilized 1Alpha-Hydroxy vitamin D
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
JP4596732B2 (ja) 2000-08-29 2010-12-15 日新化成株式会社 硬カプセル
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
JP2002302447A (ja) 2001-04-03 2002-10-18 Shimizu Pharmaceutical Co Ltd 局所投与用癌治療剤
CZ20033116A3 (cs) 2001-05-15 2004-09-15 Warner-Lambert Company Llc Způsob výroby lékové formy fenytoinu sodného užívající kompaktor
US7846475B2 (en) 2001-07-05 2010-12-07 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
US6870833B2 (en) 2001-07-20 2005-03-22 Net2Phone, Inc. Active voice messaging
US7166585B2 (en) 2001-08-22 2007-01-23 Cytochroma Inc. 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
PT1436257E (pt) 2001-10-12 2007-05-31 Cytochroma Inc Análogos oxima de calcemia baixa de 1-alfa, 25-di-hidroxivitamina d3
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
AU2002366038B2 (en) 2001-11-22 2007-08-02 Morishita Jintan Co., Ltd. Non-gelatinous capsule film compositions and capsules using the same
GB0128415D0 (en) 2001-11-27 2002-01-16 Univ Sheffield Medicaments
KR20050044655A (ko) 2001-12-03 2005-05-12 노바세아, 인크. 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
FR2829142B1 (fr) 2001-12-27 2004-02-13 Ulice Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
US20030195171A1 (en) 2002-04-05 2003-10-16 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin D formulation
CA2481486C (en) 2002-04-10 2012-06-12 Fred H. Miller Multi-phase, multi-compartment capsular system
WO2003093459A1 (en) 2002-05-02 2003-11-13 Cytochroma Inc. Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof
CA2488334C (en) 2002-06-13 2010-12-07 Johns Hopkins University 24-sulfoximine vitamin d3 compounds
PL374922A1 (en) 2002-07-05 2005-11-14 Temrel Limited Controlled release composition
TWI336260B (en) 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
DK1539115T3 (da) 2002-07-29 2008-01-28 Alza Corp Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2002368245A1 (en) 2002-09-26 2004-04-19 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
DE20321698U1 (de) 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
JP2006514695A (ja) 2002-12-16 2006-05-11 テバ ファーマシューティカル インダストリーズ リミティド ビタミンｄ誘導体の前用量投与によってアレンドロネート又は他のビスフォスフォネートの全体利用効率を高める方法
WO2004054968A2 (en) 2002-12-18 2004-07-01 Johns Hopkins University 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
CA2515641A1 (en) 2003-02-11 2004-08-26 Alza Corporation Methods and dosage forms with modified layer geometry
MXPA05011026A (es) 2003-04-14 2005-12-12 Fmc Corp Pelicula de gel termo-reversible homogenea que contiene carragenano kappa-2 y capsulas blandas hechas a partir de la misma.
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
EP1677802A2 (en) 2003-04-30 2006-07-12 Bioxell S.p.a. 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
JP5049589B2 (ja) 2003-05-07 2012-10-17 オステオロジックス エイ／エス ストロンチウム塩含有の放出制御組成物
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7207965B2 (en) 2003-06-16 2007-04-24 Solx, Inc. Shunt for the treatment of glaucoma
ES2379466T3 (es) 2003-06-26 2012-04-26 Psivida Us, Inc. Sistema de suministro de fármacos de liberación sostenida bioerosionables
AU2003903382A0 (en) 2003-07-03 2003-07-17 Medvet Science Pty Ltd Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
US7053075B2 (en) 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
WO2006007323A2 (en) 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
KR20070043806A (ko) 2004-07-29 2007-04-25 사노피-아벤티스 ｐＨ에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
AU2004325362B2 (en) 2004-12-03 2012-09-06 Council Of Scientific And Industrial Research Process of preparation of biodegradable films from semi refined kappa carrageenan
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
PL2985026T3 (pl) 2005-04-15 2023-02-20 Clarus Therapeutics, Inc. Farmaceutyczne systemy dostarczania leków hydrofobowych i zawierające je kompozycje
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es) 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
WO2007039193A1 (en) 2005-09-29 2007-04-12 Roche Diagnostics Gmbh Antibodies against 25-hydroxyvitamin d
ITFI20050206A1 (it) 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
JP5303276B2 (ja) 2005-10-12 2013-10-02 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー ２５−ヒドロキシビタミンｄ不足および欠乏を治療するための方法および製品
WO2007050975A2 (en) 2005-10-26 2007-05-03 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
EP1951208A2 (en) 2005-10-26 2008-08-06 Banner Pharmacaps Inc. Lipophilic vehicle-based dual controlled release matrix system as capsule fill
MX2008005643A (es) 2005-11-01 2008-12-09 Cp Kelco Inc Gomas diutan con alto grado de viscosidad y metodos para producirlas.
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
MXPA05014091A (es) 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus
CN101448955A (zh) 2006-01-31 2009-06-03 健康研究股份有限公司 鉴定维生素d代谢改变的方法
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
CA2882048C (en) * 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
GB0606426D0 (en) 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
EP2024436A1 (en) 2006-06-06 2009-02-18 Fmc Corporation Kappa-2 carrageenan composition and products made therefrom
US20080109983A1 (en) 2006-11-10 2008-05-15 Kegel, Llc Zero Turning Radius Lane Maintenance Machine
EP2679228B1 (en) 2006-06-21 2018-03-21 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
EP1912400A1 (en) 2006-10-10 2008-04-16 Matsushita Electric Industrial Co., Ltd. Method and apparatus for mobile IP route optimization
US20100168410A1 (en) 2006-10-27 2010-07-01 Pfizer Products Inc. Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture
WO2008097646A1 (en) 2007-02-09 2008-08-14 Schering Corporation Methods to treat and/or prevent mucositis
US8491937B2 (en) 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
US7893357B2 (en) 2007-03-20 2011-02-22 Electrolock, Inc. Roebel winding with conductive felt
EP2136814A4 (en) 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
KR101759244B1 (ko) 2007-04-25 2017-07-18 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8592401B2 (en) * 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP3225243B1 (en) 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
US20090004284A1 (en) 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
EP2042165A1 (de) 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
WO2009073946A1 (en) 2007-12-12 2009-06-18 Multi Formulations Ltd. Particles in a capsule
AU2009214048A1 (en) 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Treating hypertension with 25-hydroxyvitamin D3
BRPI0907951A2 (pt) 2008-02-13 2015-08-04 Dsm Ip Assets Bv Uso combinado de 25-hidroxivitamina d3 e vitamina d3 para melhorar a densidade mineral do osso e para tratar a osteoporose
JP5691072B2 (ja) 2008-02-13 2015-04-01 ディーエスエム アイピー アセッツ ビー．ブイ． ２５−ヒドロキシビタミンｄ３を用いた高血糖の治療
CN107412237A (zh) 2008-02-13 2017-12-01 帝斯曼知识产权资产管理有限公司 25‑羟基‑维生素d3用于影响人肌肉生理学的用途
MX2010008894A (es) 2008-02-13 2010-11-05 Dsm Ip Assets Bv Combinacion de vitamina d y 25-hidroxi-vitamina d3.
CN106853250A (zh) * 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
EP2321273B1 (en) * 2008-07-24 2014-11-19 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
CN102164588B (zh) 2008-09-24 2015-07-08 赢创罗姆有限公司 耐受乙醇影响的pH依赖性受控释放的药物组合物
ES2425762T3 (es) 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
GEP20146013B (en) 2009-01-23 2014-01-27 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Controlled release pharmaceutical or food formulation and method of preparation thereof
CH700543A2 (de) 2009-03-03 2010-09-15 Innogel Ag Film auf Basis von Stärke.
KR101760534B1 (ko) 2009-09-10 2017-07-21 에프엠씨 코포레이션 이음매 없는 알기네이트 캡슐
IT1396937B1 (it) 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
SI2552484T1 (sl) 2010-03-29 2020-07-31 Opko Ireland Global Holdings, Ltd. Postopki in sestavki za znižanje ravni paratiroidnega hormona
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR20120005228A (ko) 2010-07-08 2012-01-16 주식회사 네비팜 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법
AU2010358565B2 (en) 2010-08-04 2016-07-14 R.P. Scherer Technologies, Llc Film-forming composition for soft capsules
US20120135103A1 (en) 2010-11-30 2012-05-31 Mead Johnson Nutrition Company Staged Infant Feeding Regimen To Promote Healthy Development And Growth
KR101895764B1 (ko) 2010-12-06 2018-09-07 디에스엠 아이피 어셋츠 비.브이. 25-하이드록시비타민 d3을 사용한, 증가된 에오탁신과 관련된 질환의 치료
AU2011353202B2 (en) 2010-12-28 2015-07-09 Future Diagnostics B.V. Release reagent for vitamin D
EP2680826B1 (en) 2011-03-02 2017-08-23 D3 Pharma Limited Vitamin d composition
JP5597770B2 (ja) 2011-04-20 2014-10-01 サフン カプセル カンパニー， リミテッド 崩解度及び被膜硬度を改善した非動物性軟質カプセル被膜組成物
JP2014512388A (ja) 2011-04-20 2014-05-22 マイコ・バイオ，インコーポレーテッド 免疫反応を増進するための組成物および方法
CN102771688A (zh) 2011-05-13 2012-11-14 富曼实（上海）商贸有限公司 可食用液体填充的多糖胶囊
US20130085121A1 (en) 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
WO2014029953A1 (en) 2012-08-21 2014-02-27 Cipla Limited Hot melt extruded (hme) pharmaceutical composition of cinacalcet
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
PT106978A (pt) 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103520133B (zh) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 一种淀粉基软胶囊的制备方法
CN103495176B (zh) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 一种共混挤出法制备淀粉基软胶囊的方法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20170047265A (ko) 2014-08-07 2017-05-04 옵코 아일랜드 글로벌 홀딩스 리미티드 25-하이드록시비타민 d를 이용한 보조요법

Also Published As

Publication number Publication date
EP3636280A1 (en) 2020-04-15
ES2783980T3 (es) 2020-09-21
WO2011123476A1 (en) 2011-10-06
EP2552484A1 (en) 2013-02-06
EP2552484A4 (en) 2013-09-11
US20130137663A1 (en) 2013-05-30
CN105796530A (zh) 2016-07-27
EP3636280B1 (en) 2025-05-14
CA2797537A1 (en) 2011-10-06
PT2552484T (pt) 2020-04-03
HUE048464T2 (hu) 2020-07-28
KR20130038253A (ko) 2013-04-17
HK1222132A1 (zh) 2017-06-23
HRP20200577T1 (hr) 2020-09-18
US20230346804A1 (en) 2023-11-02
LT2552484T (lt) 2020-04-27
KR102125424B1 (ko) 2020-06-22
SMT202000167T1 (it) 2020-05-08
PL2552484T3 (pl) 2020-06-29
SI2552484T1 (sl) 2020-07-31
US11672809B2 (en) 2023-06-13
CA2797537C (en) 2021-11-23
RS60087B1 (sr) 2020-05-29
CY1123095T1 (el) 2021-10-29
CN103037902A (zh) 2013-04-10
ES3036821T3 (en) 2025-09-24
EP2552484B1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
DK2552484T3 (da) Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer
DK3495392T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2884999T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
BR112013010725A2 (pt) método, e, composição
DK2978419T3 (da) Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK3103469T3 (en) Indgivelse af terapeutiske midler til centralnervesystemet
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK2914741T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2702767T3 (da) Apparater og fremgangsmåder til hdr-billedkodning og -afkodning
DK2699553T3 (da) Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK2655370T3 (da) Sammensætninger og fremgangsmåder til modulering af FXR-receptorer
DK2593131T3 (da) Fremgangsmåder og sammensætninger til cns-levering af iduronat-2-sulfatase
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
DK2585437T3 (da) Thioacetatforbindelser, sammensætninger og fremgangsmåder til anvendelse heraf
DK3366143T3 (da) Probiotiske sammensætninger og fremgangsmåder
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed
DK2533761T3 (da) Fremgangsmåder og sammensætninger til fremstilling af aerosoler
DK2585088T3 (da) Sammensætning til forbedring af seksuel sundhed
BR112014010450A2 (pt) composição e método